Analyst Ratings For NASDAQ:NKTR – Nektar Therapeutics (NASDAQ:NKTR)
Today, Mizuho reiterated its Buy rating on NASDAQ:NKTR – Nektar Therapeutics (NASDAQ:NKTR) with a price target of $103.00.
Some recent analyst ratings include
- 4/17/2018-Mizuho Reiterated Rating of Buy.
- 4/13/2018-Piper Jaffray initiated coverage with a Overweight rating.
- 3/2/2018-Cowen Reiterated Rating of Buy.
Recent Insider Trading Activity For NASDAQ:NKTR – Nektar Therapeutics (NASDAQ:NKTR)
NASDAQ:NKTR – Nektar Therapeutics (NASDAQ:NKTR) has insider ownership of 5.44% and institutional ownership of 96.32%.
- On 4/9/2018 Stephen K Doberstein, SVP, sold 160,000 with an average share price of $93.06 per share and the total transaction amounting to $14,889,600.00.
- On 4/6/2018 Robert Chess, Director, sold 25,000 with an average share price of $92.14 per share and the total transaction amounting to $2,303,500.00.
- On 4/5/2018 Maninder Hora, SVP, sold 20,000 with an average share price of $101.75 per share and the total transaction amounting to $2,035,000.00.
- On 3/7/2018 Christopher A Kuebler, Director, sold 40,000 with an average share price of $97.60 per share and the total transaction amounting to $3,904,000.00.
- On 3/7/2018 John Nicholson, COO, sold 220,144 with an average share price of $99.27 per share and the total transaction amounting to $21,853,694.88.
- On 2/16/2018 Gil M. Labrucherie, CFO, sold 3,477 with an average share price of $82.94 per share and the total transaction amounting to $288,382.38.
- On 2/16/2018 Howard W Robin, CEO, sold 12,788 with an average share price of $82.94 per share and the total transaction amounting to $1,060,636.72.
Recent Trading Activity for NASDAQ:NKTR – Nektar Therapeutics (NASDAQ:NKTR)
Shares of NASDAQ:NKTR – Nektar Therapeutics closed the previous trading session at 93.46 down -0.01 0.01% with 95.01000213623047 shares trading hands.